$0.07
7.79% yesterday
Nasdaq, Oct 03, 06:40 pm CET
ISIN
BSP733981026
Symbol
NYMXF

Nymox Pharmaceutical Corp Stock price

$0.07
+0.02 32.65% 1M
-0.07 52.55% 6M
-0.04 35.00% YTD
-0.06 45.83% 1Y
-0.36 84.52% 3Y
-2.37 97.33% 5Y
-3.19 98.00% 10Y
-2.09 96.98% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.00 7.79%
ISIN
BSP733981026
Symbol
NYMXF
Industry

Key metrics

Basic
Market capitalization
$6.2m
Enterprise Value
$6.1m
Net debt
positive
Cash
$70.0k
Shares outstanding
94.5m
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-1,035.9%
Return on Equity
66.3%
ROCE
21.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-1.4m | -
EBIT
$-1.4m | -
Net Income
$-1.6m | -
Free Cash Flow
$-2.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
82.7% | -
EBIT
82.7% | -
Net Income
82.3% | -
Free Cash Flow
36.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
$0.0
Short interest
4.7%
Employees
18
Rev per Employee
$0.0
Show more

Is Nymox Pharmaceutical Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Financial data from Nymox Pharmaceutical Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 0.31 0.31
93% 93%
-
- Research and Development Expense 1.14 1.14
71% 71%
-
-1.44 -1.44
83% 83%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -1.44 -1.44
83% 83%
-
Net Profit -1.57 -1.57
82% 82%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nymox Pharmaceutical Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Head office Bahamas
CEO Paul Averback
Employees 18
Founded 1995
Website nymox.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today